TY - JOUR
T1 - Polygenic risk modeling for prediction of epithelial ovarian cancer risk
AU - The Ovarian Cancer Association Consortium
A2 - Dareng, Eileen O.
A2 - Tyrer, Jonathan P.
A2 - Barnes, Daniel R.
A2 - Jones, Michelle R.
A2 - Yang, Xin
A2 - Aben, Katja K. H.
A2 - Adank, Muriel A.
A2 - Agata, Simona
A2 - Andrulis, Irene L.
A2 - Anton-Culver, Hoda
A2 - Antonenkova, Natalia N.
A2 - Aravantinos, Gerasimos
A2 - Arun, Banu K.
A2 - Augustinsson, Annelie
A2 - Balmana, Judith
A2 - Bandera, Elisa, V
A2 - Barkardottir, Rosa B.
A2 - Barrowdale, Daniel
A2 - Beckmann, Matthias W.
A2 - Beeghly-Fadiel, Alicia
A2 - Benitez, Javier
A2 - Bermisheva, Marina
A2 - Bernardini, Marcus Q.
A2 - Bjorge, Line
A2 - Black, Amanda
A2 - Bogdanova, Natalia, V
A2 - Bonanni, Bernardo
A2 - Borg, Ake
A2 - Brenton, James D.
A2 - Budzilowska, Agnieszka
A2 - Butzow, Ralf
A2 - Buys, Saundra S.
A2 - Cai, Hui
A2 - Caligo, Maria A.
A2 - Campbell, Ian
A2 - Cannioto, Rikki
A2 - Cassingham, Hayley
A2 - Chang-Claude, Jenny
A2 - Chanock, Stephen J.
A2 - Chen, Kexin
A2 - Chiew, Yoke-Eng
A2 - Chung, Wendy K.
A2 - Claes, Kathleen B. M.
A2 - Colonna, Sarah
A2 - Cook, Linda S.
A2 - Couch, Fergus J.
A2 - Daly, Mary B.
A2 - Dao, Fanny
A2 - Davies, Eleanor
A2 - de la Hoya, Miguel
A2 - Nikitina-Zake, Liene
N1 - Funding Information:
ADF has received a research grant from AstraZeneca, not directly related to the content of this manuscript. MWB conducts research funded by Amgen, Novartis and Pfizer. PAF conducts research funded by Amgen, Novartis and Pfizer. He received Honoraria from Roche, Novartis and Pfizer. AWK reports research funding to her institution from Myriad Genetics for an unrelated project. UM owns stocks in Abcodia Ltd. Rachel A. Murphy is a consultant for Pharmavite. The other authors declare no conflicts of interest.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
AB - Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
UR - http://www.scopus.com/inward/record.url?scp=85126235376&partnerID=8YFLogxK
U2 - 10.1038/s41431-021-00987-7
DO - 10.1038/s41431-021-00987-7
M3 - Article
C2 - 35027648
SN - 1018-4813
VL - 30
SP - 349
EP - 362
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 3
ER -